Interleukin23 in Systemic Lupus
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: interleukin 23.
- Who it may be relevant to
- Registry conditions: Systemic Lupus Erythematosus Related Interstial Lung Disease. Basic parameters: 18 years — 60 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Role of Interleukin 23 in Systemic Lupus Erythematosus Related Interstial Lung Disease
Overview
assement of interleukin 23 in serum of patients with systemic lupus erythematosus related interstial lung disease .
Detailed description
for all patients detailed history taken clinical and rhumatological examination will be assessed and SLEDAI score will be collected from the case record of the patients\&laboratory investigation included 1\_erythrocytic sedimentation rate.2\_complete blood count.3\_interleukin23 .4\_complement 3\&4.5\_Antinuclear Antibodies.6\_Anti double stranded antibodies.7\_full basic biochemical test(24 urine protien)8\_high resolution computed tomography.
Interventions
- Biological interleukin 23
assessment of interleukin 23 in Sera of patients using ELIZA
Primary outcome measures
- interleukin 23 [Time frame: 2 years]
Eligibility criteria
Inclusion criteria
- patients with systemic lupus erythematous and patients with systemic lupus erythematosus with interstial lung disease.
Exclusion criteria
- patients with chest conditions rather than interstial lung disease \&who receiving biological blocking antibodies\& those treated with immunosuppressive drugs.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
Egypt · 2 centers
- Sohag university hospital — Sohag
- Sohag university — Sohag
Publications
- Yap DY, Lai KN. Cytokines and their roles in the pathogenesis of systemic lupus erythematosus: from basics to recent advances. J Biomed Biotechnol. 2010;2010:365083. doi: 10.1155/2010/365083. Epub 2010 May 6. PMID 20467470
- Haroon MM, Hegazy GA, Hassanien MA, Shaker O, Hussein WH. Significance of Interleukin 23 in Systemic Lupus Patients: Relation to Disease Activity and Damage Indices. Biologics. 2023 Jan 18;17:1-9. doi: 10.2147/BTT.S389021. eCollection 2023. PMID 36698375
- Sisto M, Lisi S. Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries. J Clin Med. 2023 Sep 1;12(17):5699. doi: 10.3390/jcm12175699. PMID 37685766
- Senoo S, Taniguchi A, Itano J, Oda N, Morichika D, Fujii U, Guo L, Sunami R, Kanehiro A, Tokioka F, Yoshimura A, Kiura K, Maeda Y, Miyahara N. Essential role of IL-23 in the development of acute exacerbation of pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2021 Nov 1;321(5):L925-L940. doi: 10.1152/ajplung.00582.2020. Epub 2021 Sep 15. PMID 34524907
Identifiers
NCT: NCT06713187 · Soh_Med__24_11_09MS